James Paul Lang - 05 May 2026 Form 4 Insider Report for HALOZYME THERAPEUTICS, INC. (HALO)

Reporting relationship: Director
Issuer ticker: HALO
Reported as of: 05 May 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 07 May 2026, 19:03:43 UTC
Prior SEC filing: 09 Jan 2026
Next SEC filing: 10 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ James R. Oehler, Attorney-in-Fact

Key filing fact

James Paul Lang filed Form 4 for HALOZYME THERAPEUTICS, INC. (HALO) on 07 May 2026.

Key facts

This page summarizes James Paul Lang's Form 4 filing for HALOZYME THERAPEUTICS, INC. (HALO).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 07 May 2026, 19:03.

Change

Previous filing in this sequence was filed on 09 Jan 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001703090 Primary reporting owner

Lang James Paul

Relationship: Director
Address: 12390 EL CAMINO REAL, SAN DIEGO
Signature: /s/ James R. Oehler, Attorney-in-Fact
Signature date: 07 May 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

HALO transaction

Common Stock

Award

Transaction value
Shares: +3,796
Change %: +427%
Price: $0.000000^*
Shares after: 4,685
Date: 05 May 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

HALO transaction Derivative

Option to Purchase Common Stock

Award

Transaction value
Shares: +6,040
Change %
Price: $0.000000^*
Shares after: 6,040
Date: 05 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 6,040
Exercise price: $65.87
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents annual restricted stock unit ("RSU") grant under the Issuer's director compensation program. Each RSU represents the right to receive one share of common stock of the Issuer. This grant will vest in full on the earlier of (i) May 5, 2027 and (ii) the date of the Issuer's next annual meeting of stockholders. These stock units are subject to a written deferral election under the Issuer's Directors Deferred Equity Compensation Plan pursuant to which shares of common stock are released to the reporting person upon completion of service as a director.

Footnote F2

Represents annual stock option grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) May 5, 2027 and (ii) the date of the Issuer's next annual meeting of stockholders.